CN110167938B - 作为Janus激酶抑制剂的新的氨基-咪唑并吡啶衍生物及其医药用途 - Google Patents

作为Janus激酶抑制剂的新的氨基-咪唑并吡啶衍生物及其医药用途 Download PDF

Info

Publication number
CN110167938B
CN110167938B CN201880006261.0A CN201880006261A CN110167938B CN 110167938 B CN110167938 B CN 110167938B CN 201880006261 A CN201880006261 A CN 201880006261A CN 110167938 B CN110167938 B CN 110167938B
Authority
CN
China
Prior art keywords
acetonitrile
cyclohexyl
imidazo
pyridin
trans
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880006261.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN110167938A (zh
Inventor
J·拉森
M·拉森
L·K·拉斯穆森
A·里岑
T·M·杜斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Akileon Ltd
Original Assignee
Leo Pharma AS
Akileon Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leo Pharma AS, Akileon Ltd filed Critical Leo Pharma AS
Publication of CN110167938A publication Critical patent/CN110167938A/zh
Application granted granted Critical
Publication of CN110167938B publication Critical patent/CN110167938B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201880006261.0A 2017-01-11 2018-01-10 作为Janus激酶抑制剂的新的氨基-咪唑并吡啶衍生物及其医药用途 Active CN110167938B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17151020 2017-01-11
EP17151020.9 2017-01-11
PCT/EP2018/050548 WO2018130563A1 (en) 2017-01-11 2018-01-10 Novel amino-imidazopyridine derivatives as janus kinase inhibitors and pharmaceutical use thereof

Publications (2)

Publication Number Publication Date
CN110167938A CN110167938A (zh) 2019-08-23
CN110167938B true CN110167938B (zh) 2024-06-14

Family

ID=57777557

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880006261.0A Active CN110167938B (zh) 2017-01-11 2018-01-10 作为Janus激酶抑制剂的新的氨基-咪唑并吡啶衍生物及其医药用途

Country Status (26)

Country Link
US (1) US10703751B2 (cg-RX-API-DMAC7.html)
EP (1) EP3568396B1 (cg-RX-API-DMAC7.html)
JP (1) JP7009504B2 (cg-RX-API-DMAC7.html)
KR (1) KR102548543B1 (cg-RX-API-DMAC7.html)
CN (1) CN110167938B (cg-RX-API-DMAC7.html)
AU (1) AU2018208516B2 (cg-RX-API-DMAC7.html)
CA (1) CA3045567A1 (cg-RX-API-DMAC7.html)
CY (1) CY1123864T1 (cg-RX-API-DMAC7.html)
DK (1) DK3568396T3 (cg-RX-API-DMAC7.html)
ES (1) ES2846741T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20210095T1 (cg-RX-API-DMAC7.html)
HU (1) HUE052720T2 (cg-RX-API-DMAC7.html)
IL (1) IL267829B (cg-RX-API-DMAC7.html)
LT (1) LT3568396T (cg-RX-API-DMAC7.html)
MX (1) MX389378B (cg-RX-API-DMAC7.html)
MY (1) MY195576A (cg-RX-API-DMAC7.html)
NZ (1) NZ754922A (cg-RX-API-DMAC7.html)
PL (1) PL3568396T3 (cg-RX-API-DMAC7.html)
PT (1) PT3568396T (cg-RX-API-DMAC7.html)
RS (1) RS61317B1 (cg-RX-API-DMAC7.html)
RU (1) RU2019125177A (cg-RX-API-DMAC7.html)
SI (1) SI3568396T1 (cg-RX-API-DMAC7.html)
TW (1) TWI760419B (cg-RX-API-DMAC7.html)
UA (1) UA123972C2 (cg-RX-API-DMAC7.html)
WO (1) WO2018130563A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201904190B (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190144A1 (ar) 2016-12-16 2019-06-16 Janssen Pharmaceutica Nv إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز
EP4086256A1 (en) 2016-12-16 2022-11-09 Janssen Pharmaceutica NV Small molecule inhibitors of the jak family of kinases
TW202016110A (zh) 2018-06-15 2020-05-01 比利時商健生藥品公司 Ｊａｋ激酶家族之小分子抑制劑
CN112384514A (zh) * 2018-07-06 2021-02-19 利奥制药有限公司 作为janus激酶抑制剂的新的氨基-咪唑并嘧啶衍生物及其药物用途
CN114555595B (zh) * 2019-08-30 2023-12-26 Tsd生命科学有限公司 咪唑并吡啶衍生物及将其作为有效成分的药学组合物
CA3213134A1 (en) 2021-03-11 2022-09-15 Janssen Pharmaceutica Nv Lorpucitinib for use in the treatment of jak mediated disorders
CN119569971B (zh) * 2025-02-07 2025-05-27 吉林大学 一种用于蛋白质磷酸化和棕榈酰化修饰同时筛选的Janus材料的制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104955824A (zh) * 2012-11-20 2015-09-30 基因泰克公司 作为含t790m的egfr突变体的抑制剂的氨基嘧啶化合物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101981033B (zh) * 2008-02-06 2015-02-04 百时美施贵宝公司 用作激酶抑制剂的取代的咪唑并哒嗪化合物
US8461328B2 (en) * 2010-01-12 2013-06-11 Genentech, Inc. Tricyclic heterocyclic compounds, compositions and methods of use thereof
CN103168032A (zh) * 2010-08-05 2013-06-19 安美基公司 抑制间变性淋巴瘤激酶的苯并咪唑和氮杂苯并咪唑化合物
EP2518071A1 (en) * 2011-04-29 2012-10-31 Almirall, S.A. Imidazopyridine derivatives as PI3K inhibitors
EP2527344A1 (en) * 2011-05-25 2012-11-28 Almirall, S.A. Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases
WO2013007768A1 (en) * 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors
WO2013007765A1 (en) 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Fused tricyclic compounds for use as inhibitors of janus kinases
UY34616A (es) * 2012-02-10 2013-09-30 Galapagos Nv Nuevo compuesto útil para el tratamiento de enfermedades degenerativas e inflamatorias.
UA117572C2 (uk) 2012-11-01 2018-08-27 Інсайт Холдинґс Корпорейшн Трициклічні конденсовані похідні тіофену як інгібітори jak
CN104098563A (zh) * 2013-04-02 2014-10-15 山东亨利医药科技有限责任公司 Jnk抑制剂化合物
TW201625643A (zh) * 2014-04-30 2016-07-16 英塞特公司 製備ｊａｋ１抑制劑之方法及其新形式
PT3509591T (pt) 2016-10-03 2021-12-27 Highlightll Pharmaceutical Hainan Co Ltd Novos inibidores seletivos da jak1 e usos dos mesmos
JOP20190144A1 (ar) 2016-12-16 2019-06-16 Janssen Pharmaceutica Nv إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104955824A (zh) * 2012-11-20 2015-09-30 基因泰克公司 作为含t790m的egfr突变体的抑制剂的氨基嘧啶化合物

Also Published As

Publication number Publication date
RU2019125177A3 (cg-RX-API-DMAC7.html) 2021-05-11
KR20190103231A (ko) 2019-09-04
RU2019125177A (ru) 2021-02-15
CA3045567A1 (en) 2018-07-19
CN110167938A (zh) 2019-08-23
PL3568396T3 (pl) 2021-05-31
US10703751B2 (en) 2020-07-07
EP3568396B1 (en) 2020-11-11
HRP20210095T1 (hr) 2021-03-05
WO2018130563A1 (en) 2018-07-19
UA123972C2 (uk) 2021-06-30
IL267829A (en) 2019-09-26
MX2019008331A (es) 2020-01-14
US20190367512A1 (en) 2019-12-05
DK3568396T3 (da) 2021-01-18
AU2018208516B2 (en) 2021-07-08
MX389378B (es) 2025-03-20
ES2846741T3 (es) 2021-07-29
CY1123864T1 (el) 2022-05-27
JP7009504B2 (ja) 2022-01-25
JP2020504186A (ja) 2020-02-06
IL267829B (en) 2022-02-01
LT3568396T (lt) 2021-02-10
NZ754922A (en) 2025-11-28
BR112019014191A2 (pt) 2020-02-11
RS61317B1 (sr) 2021-02-26
TWI760419B (zh) 2022-04-11
KR102548543B1 (ko) 2023-06-29
SI3568396T1 (sl) 2021-04-30
PT3568396T (pt) 2021-02-09
TW201829407A (zh) 2018-08-16
ZA201904190B (en) 2020-10-28
HUE052720T2 (hu) 2021-05-28
MY195576A (en) 2023-02-02
AU2018208516A1 (en) 2019-07-11
EP3568396A1 (en) 2019-11-20

Similar Documents

Publication Publication Date Title
CN110167938B (zh) 作为Janus激酶抑制剂的新的氨基-咪唑并吡啶衍生物及其医药用途
EP3190889B1 (en) Compounds inhibiting leucine-rich repeat kinase enzyme activity
EP2964223B1 (en) Compounds inhibiting leucine-rich repeat kinase enzyme activity
CA2790070C (en) Cyclobutane and methylcyclobutane derivatives as janus kinase inhibitors
CN106905322B (zh) 吡咯嘧啶五元氮杂环衍生物及其应用
CN105263934B (zh) 作为bet抑制剂的吡唑并‑吡咯烷‑4‑酮衍生物及其在治疗疾病中的用途
CA2818545A1 (en) Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
CN105452239A (zh) 作为jak抑制剂的联吡唑衍生物
KR20240055788A (ko) 신규한 ras 억제제
CN112898269A (zh) 化合物的结晶形式
WO2019011228A1 (zh) 咪唑并[1,2-b]嘧啶并[4,5-d]哒嗪-5(6H)-酮类化合物及其应用
RU2761626C2 (ru) ПРОИЗВОДНЫЕ 5-(7Н-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)-5-АЗАСПИРО[2.5]ОКТАН-8-КАРБОНОВОЙ КИСЛОТЫ В КАЧЕСТВЕ НОВЫХ ИНГИБИТОРОВ JAK-КИНАЗЫ
CN105102435A (zh) 用作激酶活性调节剂的新颖的咪唑-哌啶基衍生物
HK40013317B (zh) 作为janus激酶抑制剂的新的氨基-咪唑并吡啶衍生物及其医药用途
CA3222404A1 (en) Heterocyclic jak inhibitor
HK40013317A (en) Novel amino-imidazopyridine derivatives as janus kinase inhibitors and pharmaceutical use thereof
BR112019014191B1 (pt) Composto e composição farmacêutica
WO2025151602A1 (en) Heteroaryl compounds as ligand directed degraders of irak4
CN121219294A (zh) 作为irk4的配体定向降解剂的杂芳基化合物
WO2025087267A1 (zh) 一种含有噻唑基的哌啶并嘧啶类衍生物、其制备方法及其医药上的应用
HK40053244A (en) Pyridazinone derivative

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40013317

Country of ref document: HK

TA01 Transfer of patent application right

Effective date of registration: 20221109

Address after: Helsingborg

Applicant after: Akileon Ltd.

Address before: Rupp, Denmark

Applicant before: LEO PHARMA A/S

TA01 Transfer of patent application right
GR01 Patent grant
GR01 Patent grant